Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK healthcare professionals (HCPs) only. Prescribing Information and adverse event reporting information can be found below.
      Summary of Product Characteristics Link
      Prescribing Information Link
      Banner featuring the AQUIPTA (atogepant) tablets logo and tagline: “An oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention.” Main message reads: “Help prevent the disruption of migraine.” Background shows two individuals wearing white tops and green aprons, one with their hand on their face with a pained expression, and the other smelling a flower.
      Banner featuring the AQUIPTA (atogepant) tablets logo and tagline: “An oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention.” Main message reads: “Help prevent the disruption of migraine.” Background shows two individuals wearing white tops and green aprons, one with their hand on their face with a pained expression, and the other smelling a flower.

      UK-AQP-240034. DOP: March 2025.

      Resources

      For healthcare professionals

      Getting Started with AQUIPTA®

      To support with the initiation of AQUIPTA® for your eligible migraine patients, this leaflet provides guidance on selecting the appropriate patients, considerations for selecting the correct dose, important details for your patient to understand before starting treatment and the next steps for their treatment journey.

      To receive a copy of this leaflet, please submit your details on the Contact us page and tick Getting Started with AQUIPTA®.

      Migraine: From guidelines to clinical practice

      This podcast will explore how migraine presents in everyday primary care settings and discuss practical approaches to assessment and management grounded in current guidance. This podcast is presented by Dr David Watson, GP with Extended Role in Headache, Hamilton Medical Group, Aberdeen, Dr Lauren Wellburn, GP with Extended Role in Headache, East Park Medical Centre & Halton Medical Practice, Leeds and National Migraine Centre, Bradford Community Neurology Service and Dr Nazia Hussain, GP with Extended Role, Blackwood Medical Group.

      References

      For your patients

      Patient booklet: My Treatment with AQUIPTA® in Migraine

      To support your migraine patients treated with AQUIPTA®, this booklet provides guidance on what the medication is, how it works and details to know while taking it.

      This booklet includes a migraine diary designed to help patients keep track of their symptoms, possible triggers and medication(s) taken.

      To receive a copy of this booklet, please submit your details on the Contact us page and tick Patient booklet.

      References:

      1. AQUIPTA® Summary of Product Characteristics.

      References:

      1. AQUIPTA® Summary of Product Characteristics.

       

      Please refer to the AQUIPTA® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The AQUIPTA® Summary of Product Characteristics can be found here.

      AQUIPTA® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      References:

      1. AQUIPTA® (atogepant) Summary of Product Characteristics.
      2. Humphrey PPA. Headache 2008;48:685–7.
      3. The Migraine Trust. Heading in the wrong direction. Available at: https://migrainetrust.org/wp-content/uploads/2023/09/TMT-Heading-In-The-Wrong-Direction-2023-FINAL.pdf. Accessed March 2026.
      4. NHS RightCare. RightCare: Headache & Migraine Toolkit optimising a headache and migraine system. 2019. Available at: https://www.england.nhs.uk/rightcare/wp-content/uploads/sites/40/2020/01/rightcare-headache-and-migraine-toolkit-v1.pdf. Accessed March 2026.
      5. Martelletti P, et al. J Headache Pain 2018;19:115.
      6. Steiner TJ, et al. J Headache Pain 2024;25:91.
      7. BASH. National Headache Management System For Adults 2019. Available at: https://bash.org.uk/guidelines/. Accessed March 2026.
      8. National Headache Foundation. Self-Screeners. Available at: https://headaches.org/resources/headache-tests/. Accessed March 2026
      9. Joppekova L, et al. J Headache Pain 2025;26:149.
      10. Bron C, et al. Neuropsychiatr Dis Treat. 2021;17:1183–94.
      11. The Migraine Trust. Migraine attack triggers. Available at: https://migrainetrust.org/live-with-migraine/self-management/common-triggers/. Accessed March 2026.
      12. NICE CG150: Headaches in over 12s: diagnosis and management. Available at: https://www.nice.org.uk/guidance/cg150. Accessed March 2026.
      13. Sanger G, et al. Eur J Pharmacol. 2013;715:10–4.
      14. Ghadiri-Sani M, Silver N. BMJ Clin Evid. 2026;2016:1205.
      15. SIGN 155. Pharmacological management of migraine. A national clinical guideline. Available at: https://www.sign.ac.uk/media/2077/sign-155-migraine-2023-update-v3.pdf. Accessed March 2026.
      16. GOV.UK. Topiratmate (Topamax): Introduction of new safety measures, including a Pregnancy Prevention Programme. Available at: https://www.gov.uk/drug-safety-update/topiramate-topamax-introduction-of-new-safety-measures-including-a-pregnancy-prevention-programme. Accessed March 2026.
      17. Rivera-Mancilla E, et al. Expert Opin Drug Saf. 2020;19:1237–50.
      18. Schuster NM, Rapaport AM. Nat Rev Neurol. 2016;12:635–50.

      UK-AQP-260126 | Date of preparation: April 2026.

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250400. Date of preparation December 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.